About us
Who we are
ScreenCell is a French biotechnology company specializing in the isolation and analysis of circulating tumor cells (CTCs) from the blood of cancer patients.
Since 2010, we have been producing circulating tumor cell assays for researchers, clinicians, and laboratories studying CTCs to better understand disease progression.
With over 70 scientific publications and a presence in more than 30 countries, ScreenCell is an international leader in circulating tumor cell (CTC) isolation.
Mission
ScreenCell’s mission is driven by a deep-seated commitment: to significantly improve the care journey for cancer patients by offering personalized monitoring for each patient through our circulating tumor cell (CTC) tests.
In the near future, we hope to use CTCs to determine the effectiveness of treatment for patients and to detect potential relapses early on through a simple blood test.
Discover our latest news and company culture through our various articles.
Follow ScreenCell on LinkedIn
